Explanipedia

The double-edged sword effect of adverse childhood experiences forging adult stress into depression and anxiety Open

Zimu Gong, Jingwen Yang, Ying Wang, Wenqing Liang, Shunchao Luo , et al. · 2025

Adverse childhood experiences (ACEs) are a high risk factor for depression and anxiety in adulthood and are associated with the alterations in the hypothalamic‒pituitary‒adrenal (HPA) axis and monoamine neurotransmitters. This study aimed …

Outpatient administration of idecabtagene vicleucel: Predictors of hospitalization and impact on survival outcomes Open

Aqsa Ashraf, Zimu Gong, Taha Al‐Juhaishi · 2025

Introduction: Idecabtagene vicleucel (Ide-cel) is a BCMA-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) and is approved by FDA after at least two lines of therapy (Otero et …

Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study Open

Zimu Gong, Godsfavour Umoru, Jorge Monge, Nishi Shah, Ghulam Rehman Mohyuddin , et al. · 2024

1233 Impact of infections occurring in patients receiving immune checkpoint inhibitors for renal cell carcinoma (RCC) Open

Catherine Wiechmann, Kelly Gee, Ethan Burns, Jiaqiong Xu, Yuqi Zhang , et al. · 2023

Background Immune checkpoint inhibitor (ICI)-based regimens including pembrolizumab/axitinib (P/A), nivolumab/cabozantinib (N/C), and nivolumab/ipilimumab (N/I) have improved outcomes in patients with RCC. While immune related adverse even…

1234 Impact of infections in patients receiving immune checkpoint inhibitor therapies for non-small cell lung cancer (NSCLC) Open

Kelly Gee, Catherine Wiechmann, Ethan Burns, Jiaqiong Xu, Yuqi Zhang , et al. · 2023

Background While infections are a known cause of morbidity and mortality in those receiving chemotherapy, the burden of infections in the ICI era is seldom explored. This analysis aimed to assess incidence of infections and risk factors in…

P-409 Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving atezolizumab Open

Abdullah Esmail, Jingyu Xu, Ethan Burns, Kiera Gee, Catherine Wiechmann , et al. · 2023

Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer Open

Ethan Burns, Kelly Gee, Ryan Blair Kieser, Jiaqiong Xu, Yuqi Zhang , et al. · 2022

Background: Immune checkpoint inhibitor (ICI) therapy has significantly improved outcomes across a range of malignancies. While infections are a well-known contributor to morbidity and mortality amongst patients receiving systemic chemothe…

480 Impact of infections in patients with advanced or metastatic non-small cell lung cancer (NSCLC) receiving pembrolizumab-based therapies Open

Ethan Burns, Jiaqiong Xu, Ryan Kieser, Ibrahim N. Muhsen, Shivan Shah , et al. · 2022

Background Immune checkpoint inhibitor (ICI) therapy has improved outcomes in patients with NSCLC, particularly with the programmed death-1 inhibitor pembrolizumab. However, this therapy is not benign and while immune related toxicities ar…

Exogenous melatonin prevents type 1 diabetes mellitus–induced bone loss, probably by inhibiting senescence Open

Zimu Gong, Wacili Da, Yihao Tian, Rui Zhao, Shui Qiu , et al. · 2021

Immune Checkpoint Inhibitor–Mediated Diarrhea and Colitis: A Clinical Review Open

Zimu Gong, Yinghong Wang · 2020

Immune-mediated diarrhea and colitis (IMDC) is among the most common immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors (ICIs). Many factors will affect the risk of IMDC, including the type of I…

Genotype‐phenotype correlation of unusual <i>BCR‐ABL1</i> transcripts in Philadelphia chromosome‐positive leukaemia Open

Zimu Gong, Ting Zhou, Hui Liu, Guilin Tang, C. Cameron Yin , et al. · 2020

BCR-ABL1 is the hallmark of chronic myeloid leukaemia (CML), and is also observed in several types of acute leukaemia. The most common BCR-ABL1 transcript subtypes include e13a2 or e14a2, e1a2, and e19a2, encoding the p210 protein, p190 pr…

Comparison of treatment modalities in pancreatic pseudocyst: A population based study Open

Yanting Wang, Yazan Abu Omar, Rohit Agrawal, Zimu Gong · 2019

Laparoscopic drainage of pancreatic pseudocysts associated with the least short-term complications and had better outcomes comparing to percutaneous and open surgical drainage from 2016 National Inpatient Sample database.

Philadelphia chromosome‐negative acute leukemia in patients with chronic myeloid leukemia Open

Zimu Gong, Mina L. Xu, Mingyi Chen, Wei Cui, Hagop M. Kantarjian , et al. · 2019

To the Editor: Chronic myeloid leukemia (CML) is characterized by the presence of BCR-ABL1, usually in the form of the Philadelphia chromosome (Ph) as a result of t(9;22)(q34;q11.2). Blast phase (BP), the terminal stage of CML, often has c…

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study Open

Hamzah Abu‐Sbeih, Faisal S. Ali, Dana Alsaadi, Joseph Jennings, Wenyi Luo , et al. · 2018

Vedolizumab can be appropriate for the treatment of steroid-refractory IMDC, with favorable outcomes and a good safety profile.

Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value Open

Juliana E. Hidalgo‐Lόpez, Rashmi Kanagal‐Shamanna, Andres Quesada, Zimu Gong, Wei Wang , et al. · 2018

BACKGROUND The diagnosis of chronic myeloid leukemia (CML) is based on characteristic clinical and laboratory findings and the presence of BCR / ABL1 in the blood and/or bone marrow (BM). The utility of BM core biopsy in the workup of pati…

Revolutionary changes in salvage treatment for Hodgkin lymphoma: toward a chemotherapy-free future Open

Jiawen Chen, Wei Yang, Zimu Gong · 2018

Recently, O’Connor et al . reported the high activity of the combination of brentuximab vedotin (BV) and bendamustine in relapsed/refractory Hodgkin’s lymphoma (HL) patients (1). The study is notable for the heavily treated population and…

Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome Open

Habibe Kurt, Lan Zheng, Hagop M. Kantarjian, Guilin Tang, Farhad Ravandi‐Kashani , et al. · 2018

Cytogenetic alterations in CML: not all created equal Open

Zimu Gong, Wei Wang, Shimin Hu · 2018

The prognosis of patients with chronic myeloid leukemia (CML) has dramatically improved since the general availability of tyrosine kinase inhibitors (TKIs).Although uncommon, progression to blast phase (BP) remains a major concern in the m…

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy Open

Zimu Gong, L. Jeffrey Medeiros, Jorge E. Cortés, Zi Chen, Lan Zheng , et al. · 2017

Key Points CML patients can be stratified into 4 subgroups with different risk of blastic transformation based on cytogenetic abnormalities. TKI therapy mitigates risk of blastic transformation associated with low-risk ACAs or no ACAs but …

Extranodal nasal-type natural killer/T-cell lymphoma with penile involvement: a case report and review of the literature Open

Xiaotian Wang, Zimu Gong, Shawn Xiang Li, Wei Yan, Yongsheng Song · 2017

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia Open

Zimu Gong, L. Jeffrey Medeiros, Jorge E. Cortés, Lan Zheng, Joseph D. Khoury , et al. · 2017

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia

Erratum to: Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy Open

Zimu Gong, Lan Zheng, Zhenya Tang, Zi Chen, Wei Wang , et al. · 2017

Microarray expression profiles of long non-coding RNAs in germinal center-like diffuse large B-cell lymphoma Open

Hongyu Gao, Bin Wu, Wei Yan, Zimu Gong, Qi Sun , et al. · 2017

Long non-coding RNAs (lncRNAs) are continuously transcribed and are involved in various cellular activities. However, their contributions to the occurrence and development of germinal center B-cell (GCB)-like diffuse large B-cell lymphoma …

Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia Open

Z Chen, L. Jeffrey Medeiros, H M Kantajian, Lan Zheng, Zimu Gong , et al. · 2017

Beyond international prognostic index: risk stratification in diffuse large B-cell lymphoma Open

Hongyu Gao, Zimu Gong · 2017

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). Both the clinical behavior and the underlying biological process are very heterogeneous in DLBCL, suggesting the necessity of utilizing individ…

Zimu Gong YOU? Author Swipe